Parkman Healthcare Partners’s Xeris Biopharma Holdings XERS Stock Holding History

Parkman Healthcare Partners’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$9.98M	Buy	1,721,264 +29,679	+2%	+$197K	1.03%	35
2025 Q4	$13.3M	Sell	1,691,585 -100,089	-6%	-$788K	1.26%	28
2025 Q3	$14.6M	Sell	1,791,674 -315,809	-15%	-$2.1M	1.52%	20
2025 Q2	$9.84M	Buy	2,107,483 +327,029	+18%	+$1.5M	1.13%	30
2025 Q1	$9.77M	Buy	1,780,454 +1,201,943	+208%	+$4.85M	1.16%	31
2024 Q4	$1.96M	Buy	578,511 +476,118	+465%	+$1.53M	0.26%	72
2024 Q3	$292K	Buy	102,393 +1,563	+2%	+$4.01K	0.04%	92
2024 Q2	$227K	Buy	100,830 +154	+0.2%	+$310	0.03%	90
2024 Q1	$222K	Buy	+100,676	New	+$260K	0.03%	99

Other funds holding XERS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Parkman Healthcare Partners's XERS Position: Q1 2026 in Review

Parkman Healthcare Partners increased its Xeris Biopharma Holdings (XERS) stake by 1.8% in Q1 2026, buying an estimated $197K and bringing the position to 1,721,264 shares worth $9.98M. The position accounts for 1.03% of the portfolio, ranked #35.

Parkman Healthcare Partners first reported a position in XERS in Q1 2024 and has held it in 9 quarters since. The position peaked at $14.6M in Q3 2025. 237 funds tracked by Wall St. Rank hold XERS as of Q1 2026.

Parkman Healthcare Partners held 1,721,264 shares of Xeris Biopharma Holdings worth $9.98M as of Q1 2026.
Parkman Healthcare Partners bought 29,679 Xeris Biopharma Holdings shares in Q1 2026, an estimated $197K.
Xeris Biopharma Holdings made up 1.03% of Parkman Healthcare Partners's portfolio in Q1 2026, its #35 holding.
Parkman Healthcare Partners first reported a position in Xeris Biopharma Holdings in Q1 2024 and has held it in 9 quarters since.
Parkman Healthcare Partners's Xeris Biopharma Holdings position peaked at $14.6M in Q3 2025.
237 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2026.

Based on Parkman Healthcare Partners's 13F filing for Q1 2026, filed 15 May 2026.